All In Biotech

Free tool

FAERS Monitor: Voquezna Triple Pak

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215152 or its brand name (Voquezna Triple Pak, Amoxicillin, Clarithromycin, Vonoprazan Fumarate). Reports on generic versions are filed under their own applications.

Reports

41

Serious

4

10% of reports

Hospitalization

3

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea6
  • headache6
  • dysgeusia5
  • nausea5
  • abdominal discomfort4
  • chest discomfort3
  • drug ineffective3
  • dyspepsia3
  • fatigue3
  • off label use3
  • pain3
  • palpitations3
  • abdominal distension2
  • chills2
  • cough2

Reports by year received

View as table
YearReports
20247
202514
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,118 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dysgeusiaSignal534.515.2131
dyspepsiaSignal315.65.328
chest discomfortSignal315.05.127
palpitationsSignal313.14.423
abdominal discomfortSignal412.24.831
abdominal distension29.82.58
chills28.82.37
headacheSignal64.92.315
diarrhoeaSignal64.82.315
cough23.70.92
nauseaSignal53.21.46
pain32.50.81
fatigue32.00.71
off label use31.80.60
drug ineffective31.20.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.